BRD4 and Thrombocytopenia: Unfortunately, BET inhibitors are not selective to BRD4 alone, and the pharmacokinetic profiles of many BET inhibitors failed tremendously in the initial phases of clinical trials due to dose-limiting toxicities such as thrombocytopenia (Doroshow et al., 2017; Sun et al., 2021; Trojer, 2022).